ALZN - יחס חוב להיוון בספרים alzamend.com

Alzamend Neuro, Inc. (ALZN) is developing its AL001 lithium compound pipeline to combat dementia as it seeks expansion within the neuropharmaceutical sector. The financial stability metric of debt-to-capitalization provided by the GURU.Markets platform illustrates the capital structure dynamics, where the value of 0.00 represents the most recent figure. While risks persist due to high clinical trial failure rates, diversified raw material supply chains ensure stable drug production.

The development of AL001 and AL002 drugs against Alzheimer's disease by Alzamend Neuro, Inc. (ALZN) requires significant capital expenditures. The aggregate debt-to-book capitalization ratio measures the proportion of borrowed funds relative to equity value. This trend captures the balance between financial risk and the pace of expansion. Reducing leverage minimizes volatility, whereas its increase may accelerate clinical progress. The asset belongs to the high-risk biopharmaceutical segment.